醋酸亮丙瑞林治疗子宫腺肌病合并不孕症的研究

[Study on leuprorelin acetate in treatment of uterine adenomyosis with infertility].

作者信息

Zhou Li-ming, Zheng Juan, Sun Yi-ting, Zhao Ya-yun, Xia Ai-li

机构信息

Centre of Medical Reproduction, Ningbo Women and Children's Hospital, Ningbo, China.

出版信息

Zhonghua Fu Chan Ke Za Zhi. 2013 May;48(5):334-7.

PMID:24016474

Abstract

OBJECTIVE

To study clinical efficacy of leuprorelin acetate in treatment of uterine adenomyosis with infertility.

METHODS

From January 1,2011 to March 31,2012, 166 cycles in 166 infertile patients combined with uterine adenomyosis undergoing in vitro fertilization embryo transplant (IVF-ET) with long protocol ovum induction by leuprorelin acetate in centre of medical reproduction, ningbo women and children's hospital were studied retrospectively. In the mean time, 200 cycles in 200 infertile patients with tubal factors were enrolled as control group.The volume of uterus and outcome of IVF-ET were compared and studied between two groups.

RESULTS

(1) Volume of uterus:in adenomyosis group, after 2-6 cycles of injecting leuprorelin acetate (3.75 mg/28 days), the mean uterine volume was shrinked from (180 ± 73) cm(3) to (86 ± 67) cm(3) (P < 0.05). (2) Outcome of IVF-ET:the rate of embryo implantation was 39.1% in adenomyosis group and 35.8% in control group. The rate of clinical pregnancy was 54.2% in adenomyosis group and 53.7% in control group. The rate of abortion was 4.7% in adenomyosis group and 4.2% in control group. They all did not show statistical differences (P > 0.05). (3) In adenomyosis group, the rate of fertilization, two pronuclear (2PN) and superior embryo were 67.2%(319/475), 60.8% (289/475) and 52.9% (162/306) in patients with failed pregnancy and 74.2% (423/570), 67.7% (386/570) and 62.1% (256/412) in patients with successful pregnancy after IVF-ET, which reached significant difference (P < 0.05).

CONCLUSION

Leuprorelin acetate could improve volume of uterine adenomyosis and outcome of pregnancy in patients undergoing IVF-ET.

摘要

目的

探讨醋酸亮丙瑞林治疗子宫腺肌病合并不孕症的临床疗效。

方法

回顾性分析2011年1月1日至2012年3月31日在宁波市妇女儿童医院生殖医学中心接受体外受精胚胎移植（IVF-ET）长方案促排卵的166例子宫腺肌病合并不孕症患者的166个周期。同时，选取200例输卵管因素不孕症患者的200个周期作为对照组。比较两组患者的子宫体积及IVF-ET结局。

结果

（1）子宫体积：子宫腺肌病组在注射醋酸亮丙瑞林（3.75mg/28天）2-6个周期后，子宫平均体积由（180±73）cm³缩小至（86±67）cm³（P<0.05）。（2）IVF-ET结局：子宫腺肌病组胚胎着床率为39.1%，对照组为35.8%；临床妊娠率子宫腺肌病组为54.2%，对照组为53.7%；流产率子宫腺肌病组为4.7%，对照组为4.2%。均无统计学差异（P>0.05）。（3）子宫腺肌病组中，IVF-ET妊娠失败患者的受精率、双原核（2PN）率及优质胚胎率分别为67.2%（319/475）、60.8%（289/475）和52.9%（162/）306，妊娠成功患者分别为74.2%（423/570）、67.7%（386/570）和62.1%（256/412），差异有统计学意义（P<0.05）。